May 29, 2020 by David HaenNow’s the Time to Buy These 3 StocksThese drug developers will give your portfolio a boost.
May 24, 2020 by David Haen3 Top Pharma Stocks to Buy Right NowPromising new drugs will drive these companies' stocks skyward.
May 22, 2020 by David HaenShould You Own This Sleeper Biotech Stock?This cancer-fighting biotech could have two approved drugs in the next year, and a whole lot more.
May 19, 2020 by David HaenWhere Will Adaptimmune Be in 5 Years?Big pharma partners could help this cutting-edge cell-therapy company be successful in the future.
May 14, 2020 by David HaenWill GenMark Diagnostics' Stock Keep Rising?A coronavirus diagnostic test is fueling this biotech's revenue for 2020.
May 14, 2020 by David HaenThis Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19Third-quarter results from a COVID-19 trial could send this stock soaring.
May 10, 2020 by David HaenIs There A Safer Way to Invest in a Coronavirus Vaccine?Size may matter in the long run.
May 9, 2020 by David HaenIs Axsome Therapeutics a Screaming Buy?Two positive late-stage clinical trials may just be the beginning.
May 9, 2020 by David HaenIf You Invested $10,000 in Amarin's IPO, This Is How Much Money You'd Have NowNot all IPO returns are equal.
May 4, 2020 by David HaenShould You Buy Global Blood Therapeutics Before This Week's Earnings?On Wednesday, investors will learn the progress of its sickle cell disease drug launch.
May 2, 2020 by David HaenAstraZeneca Notches Win with Prostate Cancer DrugNew clinical trial results may lead to a label expansion this quarter for Lynparza, and huge revenue growth for the drug.
May 1, 2020 by David HaenDid Merck Just Receive a Gift From the FDA?A new, more convenient dosing schedule favors Keytruda.
Apr 30, 2020 by David HaenBetter Buy: Illumina vs. Adaptive BiotechnologiesOne company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.
Apr 29, 2020 by David HaenShould You Buy Stock Now in This New Coronavirus Drug Developer?This company's repurposed cancer drug might help patients with severe COVID-19.
Apr 28, 2020 by David HaenWill Last Week's Biotech IPO Outperform in a Recession?This cancer drug developer will have smooth sailing ahead -- at least until it reports clinical trial results next year.
Apr 26, 2020 by David HaenMyovant Squares Off with AbbVie On Endometriosis TreatmentWith positive clinical trial results and a confirmatory study expected to report this quarter, investors should dig in.
Apr 24, 2020 by David HaenBetter Buy: AnaptysBio vs. ExelixisKey clinical trial results this quarter will determine the better buy.
Apr 23, 2020 by David HaenThese 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?These companies just raised significant cash to advance promising drug pipelines.
Apr 21, 2020 by David HaenCould CVS Health Be a Millionaire-Maker Stock?Investors seek to capitalize on one of the broadest-reaching companies in healthcare.
Apr 19, 2020 by David HaenBetter Buy: Amarin vs. Aurinia PharmaceuticalsCould both of these volatile stocks be winners in the long run?
